Preferential inhibition of dizocilpine-induced hyperlocomotion by olanzapine

European Journal of Pharmacology

Volumn 368, Issue 1, 1999, Pages 1-7

  Ninan, Ipe ^a   Kulkarni, Shrinivas K ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Apomorphine; Catalepsy; Dizocilpine; Locomotion; Mesolimbic mesocortical area; Olanzapine; Stereotypy

Indexed keywords

APOMORPHINE; DIZOCILPINE; OLANZAPINE;

ANIMAL MODEL; ARTICLE; CATALEPSY; DOSE RESPONSE; EXTRAPYRAMIDAL SYMPTOM; INTRAPERITONEAL DRUG ADMINISTRATION; LIMBIC SYSTEM; LOCOMOTION; MALE; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; STEREOTYPY;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; BENZODIAZEPINES; CATALEPSY; DIZOCILPINE MALEATE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; LOCOMOTION; MALE; MICE; MICE, INBRED BALB C; MOTOR ACTIVITY; PIRENZEPINE; STEREOTYPED BEHAVIOR; STEREOTYPIC MOVEMENT DISORDER;

EID: 0032971559     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00982-0     Document Type: Article

References (36)

1. Bakshi V.P., Geyer M.A. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology. 122:1995;198-201.
2. Baldessarini, R.J., 1990. Drugs and the treatment of psychiatric disorders. In: Gilman, A.G., Rall, T.W., Nies, A.S., Taylor, P. (Eds.), The Pharmacological Basis of Therapeutics, pp. 383-435.
3. The olanzapine HGAD study group, Beasely C.M., Tolleston G., Tran P., Satterlee W., Sanger T., Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 14:1995;111-123.
4. 2A receptor antagonist MDL 100907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse - implications for psychosis. J. Neural Transm. 100:1995;225-237.
5. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13:1990;272-276.
6. Corbett R., Camacho F., Woods A.T., Kerman L.L., Fishkin R.J., Brooks K., Dunn R.W. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviours. Psychopharmacology. 120:1995;67-74.
7. Costall B., Naylor R.J. On the mode of action of apomorphine. Eur. J. Pharmacol. 21:1973;350-361.
8. Costall B., Naylor R.J. Mesolimbic and extrapyramidal sites for the mediation of stereotyped behavior patterns and hyperactivity by amphetamine and apomorphine in the rat. Adv. Behav. Biol. 21:1977;47-76.
9. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry. 148:1991;1474-1486.
10. Farber N.B., Foster J., Duhan N.L., Olney J.W. Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity. Schizophr. Res. 21:1996;33-37.
11. Gattaz W.F., Schummer B., Behrens S. Effects of zotepine, haloperidol and clozapine on MK-801-induced stereotypy and locomotion in rats. J. Neural Transm. Gen. Sect. 96:1994;227-232.
12. 3H ]MK-801-binding sites in the rat brain: a side-preference action in cortical areas Brain Res. 762:1997;216-218.
13. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience. 41:1991;1-24.
14. Hauber W. Clozapine improves dizocilpine-induced delayed alteration impairment in rats. J. Neural Transm. Gen. Sect. 94:1993;223-233.
15. Hoffman D.C. Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J. Neural Transm. Gen. Sect. 89:1992;1-10.
16. Iverson, S.D., Singh, L., Oles, R.J., Preston, C., Tricklebank, M.D., 1988. Psychopharmacological profile of the N-methyl-D-aspartate (NMDA) receptor antagonist, MK-801. In: Domino, E.F., Kamenka, J.M. (Eds.), Sigma and Phencyclidine-like Compounds as Molecular Probes in Biology. NPP Books, Ann Arbor, pp. 373-384.
17. The clozaril collaborative study group, Kane J., Honigfield G., Singer J., Meltzer H.Y. Clozapine for the treatment resistant schizophrenia. Arch. Gen. Psychiatry. 45:1988;789-796.
18. Kinon B.J., Lieberman J.A. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology. 124:1996;2-34.
19. Koek W., Woods J.H., Winger G.D. MK-801, proposed non-competitive antagonist of excitatory aminoacid neurotransmission, produces phencyclidine-like behavioural effects in pigeons, rats and rhesus monkeys. J. Pharmacol. Exp. Ther. 245:1988;969-974.
20. Lidsky T.I., Yablonskyalter E., Zuck L., Banerjee S.P. Anti-glutamatergic effects of clozapine. Neurosci. Lett. 163:1993;155-158.
21. 1A receptor antagonist, (+)-WAY 100135, on stereotyped behaviour induced by the NMDA receptor antagonist dizocilpine in rats. Eur. J. Pharmacol. 242:1993;99-104.
22. Losonczy, M.F., Davidson, M., Davis, K.L., 1987. The dopamine hypothesis of schizophrenia. In: Meltzer, H.Y. (Ed.), Psychopharmacology: The Third Generation of Progress. Raven Press, New York, pp. 715-726.
23. 2A receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. J. Neural Transm. 104:1997;561-564.
24. Martin P., Waters N., Waters S., Carlsson A., Carlsson M.L. MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride. Eur. J. Pharmacol. 335:1997;107-116.
25. Mathe J.M., Nomikos G.G., Hildebrand B.E., Hertel P., Svensson T.H. Prazocin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur. J. Pharmacol. 309:1996;1-11.
26. Matz R., Rick W., Thompson H., Gershon S. Clozapine - a potential antipsychotic agent without extrapyramidal manifestations. Curr. Ther. Res. Clin. Exp. 16:1974;687-695.
27. Moore N.A., Calligaro D.O., Wong D.T., Bymaster F., Tye N.C. The pharmacology of olanzapine and other new antipsychotic agents. Curr. Opin. Invest. Drugs. 2:1993;281-293.
28. 2 receptors in dopamine depleted animals. Psychopharmacology. 135:1998;311-317.
29. 2 receptors! Psychopharmacology. 138:1998;215-216.
30. 2 receptors in dopamine depleted animals. Psychopharmacology (in press).
31. 2A receptor antagonists block MK-801-induced stereotypy and hyperlocomotion. Eur. J. Pharmacol. 358:1998;111-116.
32. Ninan I., Kulkarni S.K. Preferential blockade by clozapine of hyperlocomotion induced by non-competitive NMDA antagonist MK-801. Ind. J. Physiol. Pharmacol. 42:1998;375-382.
33. Porter R.H., Greene J.G., Higgins D.S., Greenamyre J.T. Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilateral dopamine depletion. J. Neurosci. 14:1994;7192-7199.
34. Radhakishun F.S., Van Ree J.M. The hypomotility elicited by small doses of apomorphine seems exclusively mediated by dopaminergic systems in the nucleus accumbens. Eur. J. Pharmacol. 136:1987;41-47.
35. Verma A., Kulkarni S.K. Modulation of MK-801 response by dopaminergic agents in mice. Psychopharmacology. 107:1991;432-436.
36. Verma A., Kulkarni S.K. Differential role of dopamine receptor subtypes in thermoregulation and stereotypic behavior in naive and reserpinized rats. Arch. Int. Pharmacodyn. 324:1993;17-32.